The PBS subsidises treatment with idelalisib under the National Health Act 1953, section 85 for patients with refractory follicular B-cell non-Hodgkin’s lymphoma.
Patients must be eligible for the PBS and meet relevant restriction criteria.
Applying for initial treatment
To apply for initial authority approval to prescribe PBS subsidised idelalisib to treat refractory follicular B-cell non-Hodgkin’s either:
Applying for continuing treatment
Continuing PBS subsidised treatment with idelalisib is Authority Required (Streamlined). It doesn’t need prior authority approval from us for listed quantities and repeats.
Call the PBS authority approvals line for further information.